Sanofi (SNYNF,SNY) said the company is discontinuing the global clinical development program of tusamitamab ravtansine. An Independent Data Monitoring Committee found that tusamitamab ravtansine as a monotherapy did not meet dual primary endpoint of progression-free survival compared to docetaxel. Sanofi said it will continue exploring the potential of antibody tusamitamab-based ADCs and CEACAM5 research in several types of cancer.Chief Medical Officer and Head of Development, said: 'Although the results are not what we hoped for, our research and work to advance potentially transformative therapies in areas of high unmet need for people living with cancer will not stop.

赛诺菲表示，该公司正在停止tusamitamab ravtansine的全球临床开发计划。一个独立的数据监测委员会发现，与多西紫杉醇相比，作为单一疗法的托沙米单抗ravtansine不符合无进展生存的双重主要终点。赛诺菲表示，将继续探索基于抗体tusamitamab的ADC和CEACAM5研究在几种癌症中的潜力。首席医疗官兼发展负责人表示：“虽然结果并不是我们所希望的，但我们的研究和工作不会停止，以推进癌症患者高度未满足需求领域的潜在变革疗法。

We will continue to explore the potential of CEACAM5 as a biomarker in cancer types where it is highly expressed.'.

我们将继续探索CEACAM5作为高表达癌症类型生物标志物的潜力。”。

For More Such Health News, visit rttnews.com. For comments and feedback contact: editorial@rttnews.comBusiness News

有关更多此类健康新闻，请访问rttnews.com。如需评论和反馈，请联系：editorial@rttnews.combusiness新闻

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In October 2023

2023年10月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in August 2023

2023年8月美国食品和药物管理局（FDA）决定生物技术股